Randomized Study of Intravitreal Injection of Bevacizumab in the Treatment of Persistent Uveitic Macular Edema

Research Article

J Ophthalmol & Vis Sci. 2023; 8(2): 1078.

Randomized Study of Intravitreal Injection of Bevacizumab in the Treatment of Persistent Uveitic Macular Edema

Bouslamti A*, Bardi C, Boujaada A, Rostoum L, Hasnaoui I, Serghini L, Elhassan A and A Berraho

Ophthalmology B, Ibn-Sina University Hospital, Rabat, Morocco

*Corresponding author: Bouslamti AOphthalmology B, Ibn-Sina University Hospital, Rabat, Morocco

Received: January 19, 2023; Accepted: March 13, 2023; Published: March 20, 2023

Abstract

Objective: To assess the efficacy and safety of Bevacizumab IVT in the treatment of persistent uveitic macular edema

Methods: This is a prospective randomized interventional study of 20 eyes of 20 macular edema patients with different types of uveitis in remission but persistent to conventional therapy who were treated with Bevacizumab IVT, with short- and medium-term results collected and analyzed.

Results: The improvement in VA was significant as early as week 12, and at 12 months reached 80%. The mean logMAR VA was initially 0.78. After 1 year, it decreased to 0.57. 16 patients (80%) had at least 2 lines of VA gain at 1-year follow-up. Reinjection was required in the majority of cases. 8 patients (40%) had a 2nd IVT of Bevacizumab and 5 patients (25%) had 3 IVT of Bevacizumab.

After one or more IVT of Bevacizumab, the improvement of at least 2 lines of VA at 12, 24 weeks and 1 year were 45%, 60% and 80% respectively. 65% of our patients had a central macular thickness <300 μm at 1 year follow-up. The mean central macular thickness was initially 546.55 μm, after 1 year of follow-up, the central macular thickness was 369.95 μm. After 3 months of follow-up, there was a reduction of at least 60 μm, and after 1 year of follow-up, the reduction in central macular thickness was at least 100 μm and this affected 65% of patients. No serious ocular or systemic side effects were observed.

Conclusion: These results demonstrate that intravitreal injection of Bevacizumab in the treatment of persistent uveitic macular edema well tolerated, with short- and medium-term improvement in visual acuity and central macular thickness in a significant number of cases.

Keyswords: Persistent macular edema; Uveitis; IVT of Bevacizumab; Visual acuity; Central macular thickness

Introduction

Uveitis is a group of all inflammatory ocular diseases, a major cause of ocular morbidity and the fifth leading cause of legal blindness worldwide [1]. Macular edema can complicate anterior, intermediate, posterior uveitis and panuveitis of very different causes, including infectious or autoimmune inflammatory [2,3]. It is the major cause of significant and permanent visionloss in uveitis [4]. Medical management of uveitic macular edema includes topical and systemic Nonsteroidal Anti-Inflammatory drugs (NSAI), local and systemic corticosteroids, systemic carbonic an hydrase inhibitors, and systemic immunosuppressants [5-7]. Uveitic macular edema can be resistant or unresponsive to these therapeutic modalities and persist despite successful control of ocular inflammation, it is said to be "refractory," and therefore warrants the investigation and use of different treatment options for this entity [8]. Part of the treatment is represented by intravitreal injections of Anti-VEGF, whose results will be evaluated in the short and medium term in the treatment of refractory uveitic macular edema, both in terms of efficacy and tolerance and side effects, as well as a review of the literature.

The purpose of this study is to provide preliminary efficacy data to determine whether intravitreal injection with Bevacizumab can be considered for the treatment of macular edema secondary to uveitis and resistant to conventional therapy.

Material and Methods

The study we conducted is a prospective randomized, monocentric interventional study in patients followed and treated for uveitic macular edema refractory to treatment involving 20 eyes of 20 patients, within the department of Ophthalmology B of the Hospital of Specialties in Rabat extending from January 2021 to February 2022, with the aim of obtaining data over one year allowing a 12-month hindsight.

General criteria were included in our study: male or female, not pregnant, at least 18 years of age at the time of consent; the patient is able to understand and sign the informed consent form; the patient is able to attend the scheduled consultations, treatment schedule and paraclinical examinations; the patient has no contraindication to intravitreal injection of Bevacizumab.

As well as ophthalmologic criteria, represented by: macular edema; uveitic macular edema; macular edema recalcitrant to any topical general/periocular anti-inflammatory treatment; subconjunctival, subtenonial, general and/or intravitreal or having received systemic treatment with carbonic anydrase inhibitor or immunosuppressant.

Exclusion criteria were: contraindications to Bevacizumab; pregnant or lactating women; women of childbearing potential who are unwilling or unable to use contraception; lost to follow-up or uncooperative patients who refuse to comply with the study protocol; associated ocular disease that limits visual potential.

Results

Epidemiologic Analysis

We collected 20 eyes of 20 patients with refractory uveitic macular edema, which were analyzed prospectively: All patients had been previously diagnosed with uveitis of varying cause. Uveitis was in remission at the time of injection in all patients. In all patients, macular edema was confirmed by biomicroscopy and macular OCT. All 20 eyes received at least one intravitreal injection of Bevacizumab, with retreatment dependent on the response to the initial IVT. No patient received additional treatment during the 1-year follow-up period.

There were 12 men (60%) and 8 women (40%) in the study.

The overall mean age of our patients at the start of IVT Bevacizumab treatment was 34.45 years.

The most common pathologies found in our study were Behçet’s disease (20%), idiopathic intermediate uveitis (15%), juvenile idiopathic arthritis (15%), followed by sarcoidosis (10%), VKH disease (10%) and MS (10%) and lastly Birdshot (5%), Irvine Gass (5%), Tuberculosis (5%) and post traumatic uveitis (5%).

Macular edema was found in 45% of cases in posterior uveitis, 30% of cases in panuveitis and only in 10% of cases in the remaining types of uveitis (anterior uveitis, intermediate uveitis, parsplanitis).

Concerning the type of macular edema

- Cystoid macular edema is the most frequently encountered anatomical form of interest in 70% of our cases.

- 3 patients had a diffuse macular thickening without cystoid character (cystic pockets) and without sub-retinal fluid.

- 3 other patients, i.e. 15% of the cases, presented a DSR with an increase of the CMT (central macular thickness)

Concerning the age of macular edema and treatment received

A bolus of methylprednisolone relayed by oral prednisolone was administered in 80% of our patients, who received it at least 3 months before Bevacizumab IVT, followed or not by immunosuppressant. Only 3 patients received locoregional injections of CTC, there is only one case that was satisfied with a topical injection with oral administration of IAC (Irvine Gass).

Effectiveness Analysis - Visual Acuity

The analysis showed that the probability of VA improvement increased significantly from 12 weeks, reaching 70% at 24 weeks.

The mean initial logMAR VA was 0.78. At 1 year, the mean logMAR visual acuity was 0.57.

16 patients (80%) presented a VA gain of at least one line at the time of their last consultation (12 months). 4 of our patients, or 20% of cases, showed no improvement in their VA during the entire year of follow-up.

As shown in Table 3, the improvement in VA of at least 2 lines at 12, 24 weeks and 1 year after one or more injections was 45%, 60% and 80%, respectively.